People: Ark Therapeutics Group PLC (AKT.L)

AKT.L on London Stock Exchange

53.50GBp
28 Mar 2014
Price Change (% chg)

-- (--)
Prev Close
53.50p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
0
52-wk High
59.30p
52-wk Low
30.00p

Search Stocks

Summary

Name Age Since Current Position

Iain Ross

2013 Non-Executive Chairman of the Board

Sue Steven

Company Secretary

David Venables

2013 Non-Executive Director

David Bloxham

63 2013 Senior Non-Executive Independent Director

Charles Spicer

49 2012 Non-Executive Independent Director

Biographies

Name Description

Iain Ross

Mr. Iain Gladstone Ross is Non-Executive Chairman of the Board of Ark Therapeutics Group PLC. Following a career with multi-national companies including Sandoz, Fisons plc and Hoffman La Roche, Mr Ross joined the Board of Celltech Group plc in 1991 and was responsible for building Celltech Biologics, the contract manufacturing division which was later sold to Alusuisse Lonza. For the last 15 years he has undertaken a number of company turnarounds and start-ups as a board member on behalf of private equity groups and banks including Quadrant Healthcare plc, Allergy Therapeutics Ltd, Eden Biodesign Ltd, Phadia AB and Silence Therapeutics plc. Currently he is Non-Executive Chairman of Biomer Technology Ltd and Pharminox Ltd, a Non-Executive Director of AIM-listed Coms PLC, and is also a Non-Executive Director of Benitec Limited and Tissue Therapies Ltd, both of whose shares are traded on the Australian Securities Exchange. He is a Qualified Chartered Director of the UK Institute of Directors and Vice Chairman of the Council of Royal Holloway, University of London.

Sue Steven

David Venables

Dr. David Venables, BSc (Hons) Ph.D., is Non-Executive Director of Ark Therapeutics Group PLC. David joined the Company from Intercell where, since 2007, he had been responsible for building Intercell’s manufacturing capabilities in Europe and the USA, most recently as Chief Operating Officer of Intercell USA Inc. based in Maryland, USA. In 1993 David was awarded his PhD in Mammalian Cell Fermentation from Surrey University, after which he joined Medeva PLC in 1995 where he spent 5 years as Group Leader – Process Development. In 1998 David was appointed Head of Biotechnology at Covance and then in 2002 he moved to Q1 Biotech Ltd as Director of Operations – Biomanufacturing. Following the acquisition of Q1 Biotech by BioReliance (which was subsequently acquired by Invitrogen in 2003), David was appointed Director of Market Development and Global Manufacturing at Invitrogen. In 2004 he was appointed Director of Operations at BioReliance Europe before joining Intercell in 2007.

David Bloxham

Dr. David P. Bloxham is Senior Non-Executive Independent Director of Ark Therapeutics Group PLC. He is a scientist with a wide range of experience in most aspects of drug discovery, development, biological drug manufacture and partnering research programmes. He held senior research positions at Roche, Laboratorios Almirall SA and Celltech plc. As Research and Development Director at Celltech plc, he was closely involved with the listing of the company on the London Stock Exchange. In the last decade he has been involved in both executive and non-executive positions at a number of small biotechnology companies including Cobra Therapeutics, Cobra Biomanufacturing, Evolutec, Provalis and Profile Therapeutics. He was also Chairman of the Board of Trustees of the Babraham Institute.

Charles Spicer

Mr. Charles A. E. Spicer is Non-Executive Independent Director of Ark Therapeutics Group Plc. Mr Spicer is also a Director of SIW Holdings Limited, the custom orthopaedic implant specialist, a Director of Aircraft Medical Limited, a Director of XCounter AB and adviser to a number of life science and medical technology companies. He is Chairman of the Department of Health’s Invention for Innovation (i4i) Funding Panel, a panel member on the Health Innovation Challenge Fund and a member of the techMARK Advisory Group at the London Stock Exchange. He was previously Chief Executive of MDY Healthcare plc, the strategic healthcare investor. Prior to that, he was Head of Healthcare Corporate Finance at both Numis Securities and Nomura International advising listed clients including Gyrus, Biocompatibles, Axis-Shield, Abcam, Ark Therapeutics Group, Intercare and Protherics. He is a Governor of Gresham’s Schools.

Basic Compensation

Name Fiscal Year Total

Iain Ross

250,001

Sue Steven

--

David Venables

288,000

David Bloxham

--

Charles Spicer

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Iain Ross

0 0

Sue Steven

0 0

David Venables

0 0

David Bloxham

0 0

Charles Spicer

0 0
Search Stocks